Xella Health, a women’s precision health and telemedicine company focused on transforming how women understand their biology across every life stage, today announced the close of more than $3.7 million in pre-seed financing. The round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures, and other funds. As well as, strategic angel investors across healthcare, diagnostics, and consumer technology.
Xella is defining a new category of women’s health—one that moves beyond symptom-based care and fragmented testing to deliver integrated biological insight, clarity, and foresight. The company combines advanced multi-omic diagnostics, longitudinal data, and personalized clinician-led guidance to help women understand what’s happening in their bodies today—and what’s likely ahead—across fertility, chronic conditions, hormonal health, early cancer detection, and preventative care.
By pioneering the use of menstrual fluid alongside peripheral blood, Xella taps into powerful biological signals that have historically been ignored—being able to tell women things like the root cause of their menstrual irregularities and chronic pelvic pain, scores for egg quality and quantity, miscarriage risk, specific perimenopause stage, HRT personalization guidance, genetic predispositions for reproductive cancers, and whole body aging insights. This is healthcare that finally puts women first—giving women the power to decode what their bodies are telling them—and Know Your Code™.
Despite women making up over half the population, the healthcare system has historically treated female biology as secondary, under-researched, and episodic. Women are often dismissed, misdiagnosed, or told their symptoms are “normal,” “just stress,” or something they must learn to live with. Xella was founded to change that paradigm.
Co-Founded by industry experts, Kelly Lacob, CEO (2x Stanford, Johns Hopkins, former Mammoth Biosciences), Adriana Dantas, COO (former Roche, BD), Jesus Ching, PhD, CTO (former Mammoth Biosciences, Arc Bio).
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, Co-Founder & CEO of Xella. “Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today. Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyze translates into meaningful, actionable health outcomes rather than more noise. This funding allows us to accelerate product development and prepare for our first launch.”
Investor demand has mirrored consumer interest. Ahead of its planned Spring 2026 launch, Xella is on pace to attract more than 10,000 women to its waitlist, signaling strong appetite for a more modern, data-driven approach to women’s health.
“Xella is rethinking women’s health from the ground up—starting with the insight women need to make sense of their own biology over time,” said Ashtan Jordan, Principal at Precursor Ventures. “The team is building with a rare combination of scientific depth, product intuition, and empathy for the lived realities of women, which is exactly what’s required to create a trusted, enduring platform in healthcare.”
“Xella represents the future of proactive, personalized care enabled at scale by AI—where early detection can meaningfully change outcomes for women by going after one of the largest unsolved problems in healthcare—early, personalized detection for women,” said Margaret Coblentz, Co-Founder and General Partner at Capital F. “We’re thrilled to continue backing a team with the scientific rigor, product vision, and cultural relevance to build a category-defining company.”
The new capital will be used to finalize product development, expand strategic partnerships, and support Xella’s upcoming market launch. Xella has already made several key leadership hires, bringing on Taylor Hansen as Chief Marketing and Commercial Officer (former Moet Hennessy-Louis Vuitton, VF Corporation), Olga Sazonova, PhD as VP of Computational Biology (former GRAIL, 23andMe), and Andre De Lucca as Lead Sr. Software Engineer (former Pr3vent, Alpargatas S.A.).
For more information or to join the waitlist, visit joinxella.com.
Xella Health is redefining women’s healthcare. Our mission: to uncover the root causes behind women’s health concerns—from fertility and perimenopause to endometriosis, PCOS, early cancer detection and beyond. We’re pioneering first-of-its-kind, AI-powered multi-omic testing that makes precision medicine and concierge care accessible to all women.
This is healthcare that finally puts women first—empowering women everywhere to Know Your Code™.
marketing@xella.bio
Xella Health
